FREMONT, Calif., Nov. 24 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that Mark McDade, Chief Executive
Officer, will participate in the upcoming Lazard Capital Markets Third
Annual Life Sciences Conference in New York on Tuesday, November 28, 2006,
at 8:30 a.m. Eastern time.
A live webcast of the conference call will be available through the PDL
website: http://www.pdl.com. Please connect to this website at least 15
minutes prior to the live webcast to allow time for any software download
that may be needed to hear the webcast. A replay will be available at
http://www.pdl.com starting approximately one hour after completion of the
webcast.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life- threatening illnesses. The company currently markets and sells a
portfolio of leading products in the acute-care hospital setting in the
United States and Canada and generates royalties through licensing
agreements with top-tier biotechnology and pharmaceutical companies based
on its pioneering antibody humanization technology. Currently, PDL's
diverse product pipeline includes investigational compounds in Phase 2 or
Phase 3 clinical development for inflammation and autoimmune diseases,
cardiovascular disorders and cancer. The company's research platform is
focused on the discovery and development of antibodies for the treatment of
cancer and autoimmune diseases. For more information, please see PDL's
website at http://www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered
trademarks of PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
Ami Knoefler, Corporate and Investor
Relations of PDL BioPharma, Inc., +1-510- 284-8851,
ami.knoefler@pdl.com
|
